Pharmacological approaches to improve endothelial repair mechanisms

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 8, 2008, Pages 1071-1082

  Besler, Christian ^a,b   Doerries, Carola ^a,b   Giannotti, Giovanna ^a,b   Lüscher, Thomas F ^a,b   Landmesser, Ulf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Endothelial regeneration; Endothelium; EPC; Nitric oxide; Oxidant stress

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGODEOXYNUCLEOTIDE; BENIDIPINE; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FINGOLIMOD; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; IRBESARTAN; LOSARTAN; METOPROLOL SUCCINATE; NEBIVOLOL; NEUTRALIZING ANTIBODY; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLMESARTAN; PERINDOPRIL; PIOGLITAZONE; PLACEBO; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; STROMAL CELL DERIVED FACTOR 1;

ACUTE CORONARY SYNDROME; ADIPOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL HOMING; CELL ISOLATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL TRIAL; COLONY FORMING CELL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIMB ISCHEMIA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; REVIEW; STEM CELL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIGENS, CD; ANTIGENS, CD34; ATHEROSCLEROSIS; BENZOPYRANS; CARBAZOLES; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; ETHANOLAMINES; GLYCOPROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PEPTIDES; PPAR GAMMA; PROPANOLAMINES; RECEPTORS, ANGIOTENSIN; REGENERATION; RISK FACTORS; STEM CELLS; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 55249111075     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.8.1071     Document Type: Review

References (97)

1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109(21 Suppl. 1), II27-II33 (2004).
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115(10), 1285-1295 (2007).
3. Luscher TF, Corti R. Flow: the signal of life. Circ. Res. 95(8), 749-7/51 (2004).
4. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl. 1), 11127-11132 (2004).
5. Faxon DP, Fuster V, Libby P et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 109(21), 2617-2625 (2004).
6. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 120), 383-389 (2001).
7. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N. Engl. J. Med. 295(7), 369-377 (1976).
8. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (2), 115-126 (1999).
9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
10. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331(7), 417-424 (1994).
11. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 451(7181), 904-913 (2008).
12. Libby P. Inflammation in atherosclerosis. Nature 420 (6917), 868-874 (2002).
13. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8(11), 1249-1256 (2002).
14. Patti G, Pasceri V, Melfi R et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 111(1), 70-75 (2005).
15. Kitta Y, Nakamura T, Kodama Y et al. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. J. Am. Coll. Cardiol. 46(4), 648-655 (2005).
16. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo Evans Blue uptake in the pig aorta. Atherosclerosis 17(3), 401-417 (1973).
17. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenegis. Science 275(5302), 964-967 (1997).
18. Sorrentino SA, Bahlmann FH, Besler C et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with Type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 116(2), 163-173 (2007).
19. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105(25), 3017-3024 (2002).
20. Werner N, Priller J, Laufs U et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation; effect of 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22(10), 1567-1572 (2002).
21. Kawamoto A, Gwon HC, Iwaguro, H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103 (5), 634-637 (2001).
22. Wassmann S, Werner N, Czech T et al. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ. Res. 99(8), E74-E83 (2006).
23. Foteinos G, Hu Y, Xiao Q et al. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation 117(14), 1856-1863 (2008).
24. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348 (7), 593-600 (2003).
25. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89(1), e1-e7 (2001).
26. Thum T, Tsikas D, Stein S et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am. Coll. Cardiol. 46(9), 1693-1701 (2005).
27. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110(10), 1209-1212 (2004).
28. Fadini GP, Miorin M, Facco M et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. J. Am. Coll. Cardiol. 45 (9), 1449-1457 (2005).
29. Ghani U, Shuaib A, Salam A et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 36(1), 151-153 (2005).
30. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353(10), 999-1007 (2005).
31. Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111(22), 2981-2987 (2005).
32. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ. Res. 95(4), 343-353 (2004).
33. Aicher A, Rentsch M, Sasaki K et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischernia. Circ. Res. 100(4), 581-589 (2007).
34. Shantsila E, Watson T, Tse HF et al. New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J. Am. Coll. Cardiol. 51(6), 669-671 (2008).
35. + cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp. Hematol. 35(7), 1109-1118 (2007).
36. Sieveking DP, Buckle A, Celermajer DS et al. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 51(6), 660-668 (2008).
37. Gulati R, Jevremovic D, Peterson TE et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ. Res. 93(11), 1023-1025 (2003).
38. Sata M, Saiura A, Kunisato A et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8(4), 403-409 (2002).
39. Inoue T, Sata M, Hikichi Y et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 115(5), 553-561 (2007).
40. Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108 (3), 399-405 (2001).
41. Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108(3), 391-397 (2001).
42. Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103(24), 2885-2890 (2001).
43. Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18), 2356-2363 (2005).
44. Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110(14), 1933-1939 (2004).
45. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9(11), 1370-1376 (2003).
46. Thum T, Fraccarollo D, Galuppo P et al. Bone marrow molecular alterations after myocardial infarction: impact on endothelial progenitor cells. Cardiovasc. Res. 70(1), 50-60 (2006).
47. Hristov M, Fach C, Becker C et al. Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis 192(2), 413-420 (2007).
48. Kusuyama T, Omura T, Nishiya D et al. The effects of HMG-CoA reductase inhibitor on vascular progenitor cells. J. Pharmacol. Sci. 101(4), 344-349 (2006).
49. Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92(9), 1049-1055 (2003).
50. Spyridopoulos I, Haendeler J, Urbich C et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110(19), 3136-3142 (2004).
51. Henrich D, Seebach C, Willhelm K et al. High dosage of simvastatin reduces TNF-α-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1β in vitro. J. Surg. Res. 142(1), 13-19 (2007).
52. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron. Artery Dis. 15(5), 235-242 (2004).
53. Wang CH, Verma S, Hsieh IC et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J. Mol. Cell Cardiol. 41(1), 34-43 (2006).
54. You D, Cochain C, Loinard C et al. Combination of the Angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 325(3), 766-773 (2008).
55. Min TQ Zhu CJ, Xiang WX et al. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 18(3), 203-209 (2004).
56. Bahlmann FH, de Groot K, Mueller O et al. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45(4), 526-529 (2005).
57. Yu Y, Fukuda N, Yao EH et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am. J. Hypertens. 21(1), 72-77 (2008).
58. Yao EH, Fukuda N, Matsumoto T et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens. Res. 30(11), 1119-1128 (2007).
59. Haznedaroglu IC, Ozturk MA. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int. J. Biochem. Cell Biol. 35(6), 867-880 (2003).
60. Rodgers KE, Xiong S, Steer R et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18(4), 287-294 (2000).
61. Imanishi T, Hano T, Nishio, I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J. Hypertens. 23(1), 97-104 (2005).
62. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens. Res. 27(2), 101-108 (2004).
63. 2+ channel blocker, increases the endothelial differentiation of endothelial progenitor cells in vitro. Hypertens. Res. 29(12), 1047-1054 (2006).
64. Passacquale G, Desideri G, Croce G et al. Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation. J. Hypertens. 26(4), 737-746 (2008).
65. Matsuda Y, Akita H, Terashima M et al. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am. Heart J. 140(5), 753-759 (2000).
66. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 31 104(5), 511-514 (2001).
67. Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22), 2781-2786 (2002).
68. Loomans CJ, de Koning EJ, Staal FJ et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of Type 1 diabetes. Diabetes 53(1), 195-199 (2004).
69. Thum T, Fraccarollo D, Schultheiss M et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56(3), 666-674 (2007).
70. Wang CH, Ciliberti N, Li SH et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109(11), 1392-1400 (2004).
71. Pistrosch F, Herbrig K, Oelschlaegel U et al. PPAR-γ-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183(1), 163-167 (2005).
72. Wang CH, Ting MK, Verma S et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. 152(6), e1051-e1058 (2006).
73. Gensch C, Clever YP, Werner C et al. The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192(1), 67-74 (2007).
74. Humpert PM, Djuric Z, Zeuge U et al. Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol. Med. 14(5-6), 301-308 (2008).
75. Marx N, Duez H, Fruchart JC et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94(9), 1168-1178 (2004).
76. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288(3), H1037-H1043 (2005).
77. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298(10), 1189-1195 (2007).
78. Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298(10), 1180-1188 (2007).
79. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004).
80. Humpert PM, Neuwirth R, Battista MJ et al. SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in Type 2 diabetes. Diabetes Care 28(4), 934-936 (2005).
81. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 103(3), 921-926 (2004).
82. Bahlmann FH, DeGroot K, Duckett T et al. Endothelial progenitor cell proliferarion and differentiation is regulated by erythropoietin. Kidney Int. 64(5), 1648-1652 (2003).
83. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 134CI-1346 (2003).
84. Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin α in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20(2), 135-141 (2006).
85. George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc. Res. 68(2), 299-306 (2005).
86. Urao N, Okigaki M, Yamada H et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ. Res. 98(11), 1405-1413 (2006).
87. Nakano M, Satoh K, Fukumoto Y et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res. 100(5), 662-669 (2007).
88. Santhanam AV, d'Uscio LV, Peterson TE et al. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 29(8), 1451-1455 (2008).
89. Barter PJ, Nicholls S, Rye KA et al. Antiinflammatory properties of HDL. Circ. Res. 95(8), 764-772 (2004).
90. Tso C, Martinic G, Fan WH et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26(5), 1144-1149 (2006).
91. Sumi M, Sata M, Miura S et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27(4), 813-818 (2007).
92. Feng Y, Jacobs F, Van Craeyveld E et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 28(2), 278-283 (2008).
93. Peterson SJ, Husney D, Kruger AL et al. Long-term treatment with the apolipoprotein A1 mimetic peptide ncreases antioxidants and vascular repair in Type I diabetic rats. J. Pharmacol. Exp. Ther. 322(2), 514-520 (2007).
94. van Oostrom O, Nieuwdorp M, Westerweel PE et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 27(8), 1864-1865 (2007).
95. Walter DH, Rochwalsky U, Reinhold J et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol. 27(2), 275-282 (2007).
96. Noor R, Shuaib U, Wang CX et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 192(1), 92-99 (2007).
97. Schmidt D, Achermann J, Odermatt B et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation 116(11 Suppl.), 164-170 (2007).